Dan Gabriel Duda

This study identifies SPHK2 as a therapeutic target in G3MB, showing that its inhibition restores anti-tumor immunity and improves survival in mouse models, with enhanced effects when combined with radiation.

This study shows that B-cell depletion or TIM-1 targeting enhances immunotherapy efficacy in HCC by reducing B-cell-mediated immunosuppression and improving antigen presentation.

This study shows that blocking CXCR4 and PD-1 together improves dendritic cell activation and immune responses against HCC in mouse models.

This paper identifies a novel HDAC inhibitor, STR-V-53, that effectively targets HCC and enhances immunotherapy responses in mouse models.

Liver fibrosis limits the survival benefit of multikinase inhibitor immunotherapy in hepatocellular carcinoma by promoting innate immune-mediated hepatotoxicity despite preserved tumor control.